The invention relates to salts and pharmaceutically acceptable polymorphic substances, solvates, hydrates, anhydrates, co-crystalline, anhydrous substances or amorphous forms of a novel pyrazolo pyrimidinone compound represented by the general formula (I), and pharmaceutical compositions and medicine unit dosage forms containing the above substances. X represents an organic or inorganic acid, and preferably maleic acid, succinic acid, hydrochloric acid, methanesulfonic acid, and the like. The invention also relates to a co-crystalline or complex of the pyrazolo pyrimidinone compound, and pharmaceutical compositions containing the co-crystalline or complex. The invention also relates to a method for preparing the substances, the applications of the substances, and pharmaceutical preparations containing the salts and crystal forms.